Avidity Partners Management’s Caribou Biosciences CRBU Stock Holding History

Avidity Partners Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,785,352	Closed	-$29.7M	–	90
2024 Q1	$29.7M	Sell	5,785,352 -574,860	-9%	-$3.54M	0.96%	38
2023 Q4	$36.4M	Buy	6,360,212 +310,000	+5%	+$1.53M	1.33%	37
2023 Q3	$28.9M	Buy	6,050,212 +3,291,612	+119%	+$20.4M	1.16%	40
2023 Q2	$11.7M	Hold	2,758,600	–	–	0.41%	70
2023 Q1	$14.6M	Sell	2,758,600 -124,000	-4%	-$772K	0.49%	60
2022 Q4	$18.1M	Sell	2,882,600 -290,000	-9%	-$2.58M	0.39%	54
2022 Q3	$33.5M	Buy	3,172,600 +222,600	+8%	+$2.07M	0.68%	47
2022 Q2	$16M	Buy	2,950,000 +130,933	+5%	+$1M	0.37%	42
2022 Q1	$25.9M	Buy	2,819,067 +145,000	+5%	+$1.53M	0.54%	47
2021 Q4	$40.4M	Buy	2,674,067 +200,000	+8%	+$3.89M	0.86%	39
2021 Q3	$59.1M	Buy	+2,474,067	New	+$60.5M	1.31%	29

Other funds holding CRBU

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Avidity Partners Management's CRBU Position: Q2 2024 in Review

Avidity Partners Management sold out of Caribou Biosciences (CRBU) in Q2 2024, closing a stake of 5,785,352 shares — an estimated $29.7M sold.

Avidity Partners Management first reported a position in CRBU in Q3 2021 and held it in 11 quarters. The position peaked at $59.1M in Q3 2021. 140 funds tracked by Wall St. Rank hold CRBU as of Q2 2024.

Avidity Partners Management reported no remaining Caribou Biosciences position as of Q2 2024 after selling out during the quarter.
Avidity Partners Management sold 5,785,352 Caribou Biosciences shares in Q2 2024, an estimated $29.7M.
Avidity Partners Management first reported a position in Caribou Biosciences in Q3 2021 and held it in 11 quarters.
Avidity Partners Management's Caribou Biosciences position peaked at $59.1M in Q3 2021.
140 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2024.

Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.